CCG-1423

CCG-1423 is an inhibitor of Rho/MRTF/SRF pathway. CCG-1423 shows activities in several cancer cells. CCG-1423 is a promising lead compound for the development of novel pharmacologic tools, and it can be used for the research of cancer and diabetes^[1][2][3]. IC50 & Target: IC50: 1.5 µM (Rho-pathway selective serum response element-luciferase reporter)^[1] In Vitro: CCG-1423 (10 µM; 24 h) affects invasion by cultured PC-3 cells into a Matrigel matrix and inhibits 54% mitochondrial metabolism of WST-1^[1].
CCG-1423 (0-100 µM; 24 h) inhibits RhoA and RhoC signaling pathways with an IC₅₀ value of 1.5 µM for Rho-pathway selective serum response element-luciferase reporter^[1].
CCG-1423 (1 µM; 16 h) improves glucose uptake in both L6 cells and primary human myotubes^[2].
CCG-1423 (10 µM; 18-19 h) inhibits expression of Rho downstream^[2].
CCG-1423 (3 µM; 25 h) selectively stimulates apoptosis of RhoC-overexpressing melanoma cell line (A375M2) compared with the parental cell line (A375)^[3]. In Vivo: CCG-1423 (0.15 mg/kg; i.p. once daily for two weeks) affects glucose tolerance and insulin levels in HFD-fed mice^[1].